ReviewReproductive biology and endocrinology : RB&E2003
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
Review in Reproductive biology and endocrinology : RB&E, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients.European journal of clinical pharmacology · 2020Pooled it
- Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.Experimental hematology & oncology · 2026Review
- Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer.Journal of ovarian research · 2025Article
- Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.International journal of preventive medicine · 2020Review
- Genistein Inhibits Proliferation ofJournal of cancer prevention · 2019Article
- Novel Associations between BRCA1 Variants C.181 T>G (Rs28897672) and Ovarian Crisk in Saudi Females.Journal of medical biochemistry · 2019Article
- Low Expression of Occludin in the Melanoma Patient.Iranian journal of pathology · 2019Article
- BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding.Human mutation · 2018Article
- Interleukin gene polymorphisms in Chinese Han population with breast cancer, a case-control study.Oncotarget · 2018Article
- Sei-1 promotes double minute chromosomes formation through activation of the PI3K/Akt/BRCA1-Abraxas pathway and induces double-strand breaks in NIH-3T3 fibroblasts.Cell death & disease · 2018Article
- Article
- DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review).Molecular medicine reports · 2014Review
- Breast and Ovarian Cancer Risk due to Prevalence of BRCA1 and BRCA2 Variants in Pakistani Population: A Pakistani Database Report.Journal of oncology · 2011Article
- Negative Regulation of AKT Activation by BRCA1.Cancer research · 2008Article
- Functional analysis of the transcription repressor PLU-1/JARID1B.Molecular and cellular biology · 2007Article
- High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer.Journal of genetics · 2007Article
- Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data.BMC cancer · 2006Article
- Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability.British journal of cancer · 2005Article
- Cell cycle and no end.Virchows Archiv : an international journal of pathology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations within the BRCA1 tumor suppressor gene occur frequently in familial epithelial ovarian carcinomas but they are a rare event in the much more prevalent sporadic form of the disease. However, decreased BRCA1 expression occurs frequently in sporadic tumors, and the magnitude of this decrease has been correlated with increased disease progression. The near absence of somatic mutations consequently suggests that there are alternative mechanisms that may contribute to the observed loss of BRCA1 in sporadic tumors. Indeed, both allelic loss at the BRCA1 locus and epigenetic hypermethylation of the BRCA1 promoter play an important role in BRCA1 down-regulation; yet these mechanisms alone or in combination do not always account for the reduced BRCA1 expression. Alternatively, misregulation of specific upstream factors that control BRCA1 transcription may be a crucial means by which BRCA1 is lost. Therefore, determining how regulators of BRCA1 expression may be co-opted during sporadic ovarian tumorigenesis will lead to a better understanding of ovarian cancer etiology and it may help foster the future development of novel therapeutic strategies aimed at halting ovarian tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.